Media Summary: In this video, Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses what could be Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some insights into Watch the full course and our most up-to-date content here: Create a free account to track ...

What Is Considered An Optimal Response When Treating A Patient With Myeloma With Car T - Detailed Analysis & Overview

In this video, Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses what could be Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some insights into Watch the full course and our most up-to-date content here: Create a free account to track ... Dr. Michael Bishop discusses the importance of long-term care and monitoring for A one-time infusion of an investigational A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship Cancer ...

In this video, Philippe Moreau, MD, Nantes University Hospital, Nantes, France, discusses risk factors for In this Clinic Conversation of the Week, Rahul Banerjee, MD, FACP, Assistant Professor of Medicine at Fred Hutchinson Cancer ... In this episode, Dr. Brian G.M. Durie discusses if Prof Deepu Madduri presents data from the CARTITUDE-1 study during a press conference at the ASH 2019 meeting. The study ... Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses challenges with Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, expresses optimism regarding current immunotherapeutic ...

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, talks on the quality of life (QoL) of

Photo Gallery

What is considered an "optimal" response when treating a patient with myeloma with CAR-T?
Treating Multiple Myeloma with Immunotherapy/CAR T-cell Therapy | Mass General Brigham
Patient responses to CAR-T therapy and factors that may influence these responses
Is CAR T cell therapy the closest thing we have to a cure in multiple myeloma? #KnowMyeloma
How Quickly Do Patients See Results After CAR-T Cell Therapy?
Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop | #ASH24
Clinical activity seen with anti-BCMA CAR T-Cell therapy for heavily pre-treated multiple myeloma
Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
CAR T-cell therapy treating myeloma
CAR T-Cell Therapy For Multiple Myeloma - Michael's Story - Nebraska Medicine
CAR T Therapy: Successes and Risks in Multiple Myeloma
Sponsored
Sponsored
View Detailed Profile
What is considered an "optimal" response when treating a patient with myeloma with CAR-T?

What is considered an "optimal" response when treating a patient with myeloma with CAR-T?

In this video, Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses what could be

Treating Multiple Myeloma with Immunotherapy/CAR T-cell Therapy | Mass General Brigham

Treating Multiple Myeloma with Immunotherapy/CAR T-cell Therapy | Mass General Brigham

What is immunotherapy and how is

Sponsored
Patient responses to CAR-T therapy and factors that may influence these responses

Patient responses to CAR-T therapy and factors that may influence these responses

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some insights into

Is CAR T cell therapy the closest thing we have to a cure in multiple myeloma? #KnowMyeloma

Is CAR T cell therapy the closest thing we have to a cure in multiple myeloma? #KnowMyeloma

Every share helps someone learn about

How Quickly Do Patients See Results After CAR-T Cell Therapy?

How Quickly Do Patients See Results After CAR-T Cell Therapy?

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ...

Sponsored
Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop | #ASH24

Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop | #ASH24

Dr. Michael Bishop discusses the importance of long-term care and monitoring for

Clinical activity seen with anti-BCMA CAR T-Cell therapy for heavily pre-treated multiple myeloma

Clinical activity seen with anti-BCMA CAR T-Cell therapy for heavily pre-treated multiple myeloma

A one-time infusion of an investigational

Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma

Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma

A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship Cancer ...

Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy

Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy

In this video, Philippe Moreau, MD, Nantes University Hospital, Nantes, France, discusses risk factors for

CAR T-cell therapy treating myeloma

CAR T-cell therapy treating myeloma

Those are big challenges for

CAR T-Cell Therapy For Multiple Myeloma - Michael's Story - Nebraska Medicine

CAR T-Cell Therapy For Multiple Myeloma - Michael's Story - Nebraska Medicine

After conventional

CAR T Therapy: Successes and Risks in Multiple Myeloma

CAR T Therapy: Successes and Risks in Multiple Myeloma

In this Clinic Conversation of the Week, Rahul Banerjee, MD, FACP, Assistant Professor of Medicine at Fred Hutchinson Cancer ...

Challenges with the real-world use of CAR-T therapy in multiple myeloma

Challenges with the real-world use of CAR-T therapy in multiple myeloma

... of

CAR T-cells in myeloma: patients’ perspective

CAR T-cells in myeloma: patients’ perspective

CAR T

Why isn't CAR T-cell therapy used first?

Why isn't CAR T-cell therapy used first?

"Why isn't

Should myeloma patients stop their current treatment and switch to CAR T-cell therapy?

Should myeloma patients stop their current treatment and switch to CAR T-cell therapy?

In this episode, Dr. Brian G.M. Durie discusses if

Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate

Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate

Prof Deepu Madduri presents data from the CARTITUDE-1 study during a press conference at the ASH 2019 meeting. The study ...

Causes for Relapse in Multiple Myeloma With CAR T cells

Causes for Relapse in Multiple Myeloma With CAR T cells

Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses challenges with

Overcoming challenges in CAR T-cell therapy for multiple myeloma

Overcoming challenges in CAR T-cell therapy for multiple myeloma

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, expresses optimism regarding current immunotherapeutic ...

Improving the QoL of patients with multiple myeloma treated with CAR-T therapy

Improving the QoL of patients with multiple myeloma treated with CAR-T therapy

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, talks on the quality of life (QoL) of